Barinthus Biotherapeutics plc
BRNS
$0.63
-$0.01-1.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 221.43% | -30,700.00% | |||
| Gross Profit | -221.43% | 30,700.00% | |||
| SG&A Expenses | -70.86% | -66.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -502.78% | -453.85% | |||
| Total Operating Expenses | -52.27% | -53.48% | |||
| Operating Income | 52.27% | 53.48% | |||
| Income Before Tax | 23.78% | 30.77% | |||
| Income Tax Expenses | 19.72% | -184.00% | |||
| Earnings from Continuing Operations | 23.80% | 31.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 160.00% | 150.00% | |||
| Net Income | 23.86% | 31.05% | |||
| EBIT | 52.27% | 53.48% | |||
| EBITDA | 54.84% | 51.28% | |||
| EPS Basic | 24.18% | 31.59% | |||
| Normalized Basic EPS | 54.60% | 52.93% | |||
| EPS Diluted | 24.56% | 31.25% | |||
| Normalized Diluted EPS | 54.60% | 52.93% | |||
| Average Basic Shares Outstanding | 0.43% | 0.79% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||